Introduction
============

The comparative genomics era has provided great opportunities for deciphering and comparing the genes, mutated to cause human genetic diseases, with respect to nondisease (ND) genes. Understanding the mutational basis of such human diseases helps to identify the candidate disease genes, which are still unexplored and thus benefit therapeutic drug designing ([@evu220-B23]; [@evu220-B2]). In this context, estimation of protein sequence evolutionary rate (the ratio of nonsynonymous nucleotide substitutions rate d*N* to synonymous substitutions rate d*S*) is of immense importance ([@evu220-B69]). However, the signatures of protein evolution in human disease genes remain a controversial issue till date. In 2003, [@evu220-B60] first demonstrated that disease genes evolve higher than ND genes. In 2004, [@evu220-B44] noticed that disease genes have larger conservation scores compared with ND genes. Interestingly, in the same year, [@evu220-B27] established that evolutionary rates do not vary between disease and ND genes. After dividing human disease genes into two groups according to 1) Mendelian disease phenotypes and 2) complex disease phenotypes, [@evu220-B6] claimed that evolutionary rates are slow in Mendelian disease genes, intermediate in ND genes, and fast in complex disease genes. In 2009, [@evu220-B8] confirmed that stronger purifying selection acts on human disease genes, and therefore, both (Mendelian and complex) disease genes are conserved than ND genes. Later on, considering monogenic (Mendelian) and polygenic (complex) disease genes, [@evu220-B54] found that ND genes are the most conserved group, whereas polygenic disease genes are the least conserved among the three gene sets. Although all the previous studies have emphasized on human disease genes classified based on the number of genes involved in a particular phenotype (Mendelian/complex), it will be interesting to analyze disease genes classified based on the number of phenotypes they are involved in. Hence, for the first time, we aim to investigate the evolutionary rates of human monogenic (Mendelian) disease genes after classifying them according to their number of phenotypic defects. Our study in Mendelian disease genes will also provide insights into the similar events in complex disease genes as approximately 54% of the Mendelian disease genes are also involved in complex diseases ([@evu220-B31]).

Pleiotropy, a phenomenon in the perspective of human diseasome, refers to diverse pathological effects of different mutations in a single gene causing distinct disorders in an individual ([@evu220-B11]). Such type of gene can be termed as "shared disease (SHD)" gene ([@evu220-B11]). Conversely, a gene can be termed as "specific disease (SPD)" gene, if it is associated with a single phenotypic defect originated from a single genetic mutation ([@evu220-B11]). Here, the focus of this study is to know whether selective constraints differ among SHD, SPD, and ND genes, specifically within similar (monogenic) disease class. Describing the pace of such evolutionary changes is essential to understand how phenotypically heterogeneous diseases are generated and maintained in nature. If any difference in the rate of evolution is observed, it is likely that the number of phenotypic defects is playing the lead role. A number of additional evolutionary rate determinants including gene expression level, tissue expression breadth, and gene functionality may also influence our analyses ([@evu220-B7]; [@evu220-B16]; [@evu220-B50]; [@evu220-B5]; [@evu220-B52]; [@evu220-B10]). Hence, it is essential to include all these features in our comparative study.

Genes and their products function as components of complex networks of macromolecules, which are linked through biochemical or physical interactions. They are often represented in "interactome" network models as "nodes\" (vertices) and "edges\" (links) ([@evu220-B73]). Such network-centered approach is progressively used to interpret several pathogenic mechanisms of disease genes ([@evu220-B73]; [@evu220-B66]). In their comprehensive study, [@evu220-B73]) have identified distinct mutations those result in different defects/diseases due to specific loss or gain of edge(s) (edgetic perturbation model) or complete loss of gene product (node removal model) in the interactome network. Recently, using drug-targeted network, [@evu220-B64] have demonstrated that single-interface targets are more likely to generate side effects due to disruption of their only interaction interface by a drug (drug-perturbed model). However, to date, there is no systematic assessment of the evolutionary history of human diseases emerged from distinct network perturbations. We thus intend to study the evolutionary patterns of SHD and SPD genes through the lens of network perturbation models.

Our in silico study here demonstrates that the rates of protein evolution significantly differ among SHD, SPD, and ND genes irrespective of their gene expression levels. Although the disease classification depends on the number of phenotypic defects, we observed that the number of phenotypic defects has no effect on the mutational rate heterogeneity among our gene sets. We interestingly obtained that network perturbations, tissue expression breadth, and gene functionality have substantial contributions to the evolutionary rate variations of SHD, SPD, and ND genes. Further in-depth investigations on network perturbation processes revealed that drug-induced perturbation has major impact on protein evolutionary rates than edgetic perturbations.

Materials and Methods
=====================

Compiling Evolutionary Rate Information of Human Autosomal Disease/ND Genes
---------------------------------------------------------------------------

The study began with a list of total 4,419 hereditary disease genes (3,911 autosomal) from "morbid map" cataloged in the Online Mendelian Inheritance in Man (OMIM) database ([@evu220-B1]). Following [@evu220-B11], we distinguished disease genes according to the number of associated phenotypic errors and identified them as SPD gene and pleiotropic/SHD gene. Genes do not have any annotation in OMIM or Human Gene Mutation Database (HGMD Professional v.2011.4) ([@evu220-B61]) or Genetic Association Database ([@evu220-B4]) were utilized as ND genes for our investigation. Evolutionary rate (d*N*/d*S*) data were retrieved from Ensembl v.74 ([@evu220-B19]) through the BioMart interface using human--mouse orthologous pairs (\>60% sequence identity) with d*S* \< 3 ([@evu220-B62]) to avoid problems due to mutation saturation and higher estimation error. Human--mouse pair was chosen because both of them 1) are placental mammals, 2) share many common anatomical features and physiological processes, 3) demonstrate conservation of organ-specific expression, 4) have similar gene expression profiles, and 5) are functionally more similar ([@evu220-B40], [@evu220-B41]; [@evu220-B22]). Moreover, the regular use of mouse as a model organism to understand human biology and disease practically supports such orthology selection ([@evu220-B41]; [@evu220-B8]). Finally, the filtered data set of SHD (*n* = 528), SPD (*n* = 1,257), and ND (*n* = 8,783) ([supplementary table S1](http://gbe.oxfordjournals.org/lookup/suppl/doi:10.1093/gbe/evu220/-/DC1), [Supplementary Material](http://gbe.oxfordjournals.org/lookup/suppl/doi:10.1093/gbe/evu220/-/DC1) online) genes were used for subsequent comparative analyses.

Identification of "Edgetically Perturbed" Proteins
--------------------------------------------------

Binary protein--protein interaction data were collected from the Human Protein Reference Database (HPRD Release 9) ([@evu220-B55]). Identification of damaging in-frame mutations (missense mutations and in-frame insertions/deletions/indels) and deleterious single-nucleotide polymorphisms (SNPs) were achieved by using HGMD ([@evu220-B61]) and sorting intolerant from tolerant (SIFT) prediction tool ([@evu220-B59]), respectively. Combination of such physical interaction data (at least two interaction partners) and deleterious in-frame mutations (at least one) for proteins helped us to identify proteins those are subject to edgetic perturbations ([@evu220-B73]). By this way, we identified 267 SHD, 371 SPD, and 908 ND proteins associated with edgetic perturbations ("edgetically perturbed" proteins). For reassessing our result, we considered Protein Data Bank (<http://www.rcsb.org/pdb>, last accessed October 10, 2014) for structural data. We obtained 169 SHD, 209 SPD, and 340 ND proteins associated with edgetic perturbations for which structural data are available. Instead of relying on a single algorithm for deleterious mutation prediction (SIFT), we additionally checked the consistency of our result using an integrative database dbNSFP v.2.5 ([@evu220-B42]). We used the logistic regression-based deleterious mutation prediction data of dbNSFP, which includes the scores of ten different tools (SIFT, PolyPhen-2 HDIV, PolyPhen-2 HVAR, GERP++, MutationTaster, MutationAssessor, FATHMM, LRT, SiPhy, and PhyloP). In addition to the above criteria, we considered CADD score \> 25 to identify deleterious mutations in a protein ([@evu220-B35]; [@evu220-B49]). Thus, we collected 298 SHD, 487 SPD, and 1,427 ND edgetic perturbation-associated proteins for our study.

Records of Protein Domains
--------------------------

Pfam domains employed in this study were obtained using Ensembl v.74 ([@evu220-B51]; [@evu220-B66]; [@evu220-B19]). For interacting domain pairs, we used DIMA (Domain Interaction MAp) database v.3.0, which integrates 5,807 structurally known interactions imported from the reliable iPfam and 3did databases ([@evu220-B45]; [@evu220-B18]; [@evu220-B46]). Proteins supplementary data of [@evu220-B33] was used to obtain structurally resolved singlish interaction interface hubs ( ≥ 5 interaction partners + at most 2 interaction interfaces).

Analyses of Gene Expression Data
--------------------------------

mRNA-seq data were retrieved from <http://genes.mit.edu/burgelab/mrna-seq/> (last accessed October 10, 2014), which contains transcriptional data of 22 human tissue or cell-line samples and applied reads per kilobase of transcript per million algorithm to evaluate gene expression levels ([@evu220-B63]; [@evu220-B28]). For our study, a gene is defined as expressed in a tissue if its expression value is larger than *M* + 2 × MAD, where *M* and MAD are determined by *M* = median(x); $\text{MAD=median(}\left| {\text{x-}M} \right|\text{)}$ and x indicates the average expression values for the corresponding gene among all tissues ([@evu220-B28]). For each gene, we then summed up the number of over expressed tissues to compute tissue expression breadth.

Functional Categorization
-------------------------

For functional labeling, we used the GO biological processes of Ensembl database ([@evu220-B26]; [@evu220-B57]); ([@evu220-B19]). Following [@evu220-B43], we subdivided gene biological functions into two categories: 1) conserved core processes and 2) less conserved regulatory processes. In addition, we considered cell adhesion, cell division, cell communication, phosphorylation, and developmental processes under regulatory processes ([@evu220-B3]). However, DNA replication, transcription, and translation-related processes are considered under core biological processes ([@evu220-B3]). For functional enrichment test, we considered nonredundant GO annotation-based GOrilla tool (<http://cbl-gorilla.cs.technion.ac.il>, last accessed October 10, 2014), which calculates exact *P* values by implementing a hypergeometric model and is widely used due to its fast running time and rigorous statistical analysis ([@evu220-B17]).

Collection of Drug-Related Data
-------------------------------

DrugBank v.4.0 ([@evu220-B38]) was used to retrieve drugs those have at least one known human protein target. To evaluate the side effects of the drugs, we considered SIDER2 (<http://sideeffects.embl.de/>, last accessed October 10, 2014) database ([@evu220-B36]). Thereby, we compiled a list of 996 drugs associated with 4,192 side effects. However, a target protein may have association with drugs with different number of side effects. Hence, we considered a protein as side-effect-associated protein if it is targeted by drug(s) known to have at least one side effect.

Gene Length, Protein Length, and Gene Recombination Rate Estimation
-------------------------------------------------------------------

Gene length (*l*) and protein length were calculated using Ensembl v.75 ([@evu220-B19]). Chromosome-wise high-resolution recombination rates were downloaded from the International HAPMAP Consortium website ([@evu220-B29]). For a gene, we collected recombination rates at base position *i* (ρ*i*) and computed the recombination rates across the genic regions using the formula: (Σρ*i*)/*l* ([@evu220-B32]). In our gene set, we obtained recombination rate data of 435 SHD, 1,061 SPD, and 7,000 ND genes.

Analyses of Human Gene Paralogs and Protein Complex Data
--------------------------------------------------------

We retrieved human paralogous gene pairs from Ensembl v.73 database ([@evu220-B19]) and estimated the number of paralogs for each gene of our data set. We found paralog data of 426 SHD, 933 SPD, and 5,920 ND genes. Human protein complex data were collected from CORUM database ([@evu220-B58]). We define protein complex number as the count of complexes in which a particular protein participates ([@evu220-B15]). Thus, we acquired complex association number for 1,090 individual genes of our data set.

Statistical Analyses
--------------------

All statistical analyses except analysis of covariance (ANCOVA) were achieved by using SPSS v.13. Throughout the study, we used nonparametric Spearman rank correlation coefficient. To calculate difference between two data sets, Mann--Whitney *U* test (MWT) was used unless mentioned otherwise. For ANCOVA analysis, considering the pair-wise interaction terms, XLSTAT 2009 was used. To generate violin plot, we used R package v. 2.13.1 (<http://www.r-project.org>, last accessed October 10, 2014).

Results
=======

Evolutionary Rates of Shared, Specific, and ND Genes
----------------------------------------------------

The extent to which mutational changes have impacted human monogenic diseases with single (SPD) or multiple (SHD) phenotypic defect(s) can be traced by estimating the evolutionary rates of human SHD (defect number ≥ 2) and SPD (defect number = 1) genes considering ND (defect number = 0) genes as the control set. We thus observed that evolutionary rates are lower in SHD (average d*N*/d*S* = 0.112, *n* = 528), intermediate in SPD (average d*N*/d*S* = 0.121, *n* = 1,257), and higher in ND (average d*N*/d*S* = 0.132, *n* = 8,783) genes (Kruskal--Wallis test: *P* = 3.57 × 10^−5^) ([fig. 1](#evu220-F1){ref-type="fig"}). However, the variation in evolutionary rates may be due to sample size biasness. To simplify, we pooled all the genes into three bins of equal sample size according to their evolutionary rates (bin 1 \[range 0.152--0.861\]: fast evolving genes; bin 2 \[range 0.065--0.152\]: medium evolving genes; and bin 3 \[range 0.000--0.065\]: slow evolving genes). We thus noticed that the proportions of ND, SPD, and SHD genes are higher in bin 1 (*n* = 3,523), bin 2 (*n* = 3,523), and bin 3 (*n* = 3,522), respectively, compared with the other groups of genes ([fig. 2](#evu220-F2){ref-type="fig"}). The above observation suggests that the variations in evolutionary rates among monogenic disease and ND groups are not because of sample size differences. F[ig]{.smallcaps}. 1.---Evolutionary rate analyses of SHD, SPD, and ND genes. The violin plot depicts the relationships between protein evolutionary rates and number of phenotypic defects. F[ig]{.smallcaps}. 2.---Distributions of ND, SHD, and SPD genes in different evolutionary rate bin. Genes are partitioned into three equal size bins as (I) fast evolving, (II) medium evolving, and (III) slow evolving groups. *P* values of MWTs between groups are mentioned. \*\*Significant difference (*P* \< 0.01) between groups. NS, nonsignificant difference (*P* \> 0.05).

In our study, classification of human diseases is based on number of observable phenotypic defects. Hence, it is reasonable to assume that number of defects contribute significantly to the group-to-group evolutionary rate differences. To examine the same, we performed correlation analysis between the number of phenotypic defects and protein evolutionary rates. Correlation study (~Number\ of\ defects~ ρ^d^*^N^*^/d^*^S^* = −0.041, *P* = 2.27 ×10^−5^, *n* = 10,568) thus revealed that phenotypic defects may have little influence on protein evolutionary rates. However, such a weak but significant correlation could also be due to sampling bias because a large set of ND genes (phenotypic defect = 0) were included in the correlation analysis. After excluding the ND genes, the correlation becomes statistically insignificant in all three previous classified bins (bin 1: ~Number\ of\ defects~ ρ^d^*^N^*^/d^*^S^* = −0.002, *P* = 9.60 × 10^−1^, *n* = 508; bin 2: ~Number\ of\ defects~ ρ^d^*^N^*^/d^*^S^* = 0.006, *P* = 8.79 × 10^−1^, *n* = 643; bin 3: ~Number\ of\ defects~ ρ^d^*^N^*^/d^*^S^* = −0.032, *P* = 4.23 × 10^−1^, *n* = 634). We, therefore, conclude that some other constraints than number of defects may better explain the variation in rates of protein evolution in SHD, SPD, and ND genes.

Edgetic Interactome Network Perturbation and Rates of Evolution of SHD, SPD, and ND Genes
-----------------------------------------------------------------------------------------

Impact of a particular genetic abnormality is not limited to the activity of the gene product that carries it but can spread along the links of the interactome and alter the activity of gene products that do not carry any defects ([@evu220-B2]). Hence, it is quite reasonable that genes with more partners in the interactome tend to be involved in more diseases and phenotypes ([@evu220-B20]; [@evu220-B31]). Our result also corroborates the same (considering ND genes: ~Number\ of\ interaction\ partners~ ρ^Number\ of\ defects^= 0.214, *P* = 1.00 ×10^−6^, *n* = 4,739; excluding ND genes: ~Number\ of\ interaction\ partners~ ρ^Number\ of\ defects^= 0.164, *P* = 1.00 × 10^−6^, *n* = 1,310). In the interactome, progression of diseases takes place by causing several molecular defects in proteins through node removal or via edge gain/loss (edgetic perturbation) ([@evu220-B9]; et al. 2009). Because mutations associated with node removal are likely to generate incomplete fragments or nonfunctional gene products ([@evu220-B73]; [@evu220-B66]), we emphasized only on edgetic perturbation (due to deleterious mutations) model for further investigations. By using SIFT algorithm ([@evu220-B59]) for predicting deleterious mutations, we found that the proportions of edgetically perturbed proteins are significantly higher in SHD (50.57%; 267/528), intermediate in SPD (29.51%; 371/1,257), and lower in ND group (10.34%; 908/8,783) (SHD vs. SPD: *Z* score = 8.471; SHD vs. ND: *Z* score = 27.037; SPD vs. ND: *Z* score = 19.073, respectively; *P* \< 1.00 × 10^−4^ in all three cases). We reconfirmed our result by considering structural data for edgetically perturbed proteins of our data set ([table 1](#evu220-T1){ref-type="table"}). Although, SIFT algorithm is frequently used for its reported accuracy, it has some clear drawbacks ([@evu220-B39]; [@evu220-B59]). Hence, we considered dbNSFP database ([@evu220-B42]) to make more confident deleterious mutation predictions. When we identified edgetically perturbed proteins, we found that change in prediction algorithms did not alter the trend of our previous result ([table 1](#evu220-T1){ref-type="table"}). Hence, we used our previous data set (SIFT predicted) for further analyses. Table 1Proportions of Edgetically Perturbed Proteins in Our Data SetGene PairPercentages*Z* Score*P*SIFT-predicted data^a^SHD vs. SPD32.01% vs. 16.62%7.259\<1.00 × 10^−4^[^\*\*^](#evu220-TF2){ref-type="table-fn"}SHD vs. ND32.01% vs. 3.87%27.622\<1.00 × 10^−4^[^\*\*^](#evu220-TF2){ref-type="table-fn"}SPD vs. ND16.62% vs. 3.87%18.605\<1.00 × 10^−4^[^\*\*^](#evu220-TF2){ref-type="table-fn"}dbNSFP-predicted dataSHD vs. SPD56.44% vs. 38.74%6.875\<1.00 × 10^−4^[^\*\*^](#evu220-TF2){ref-type="table-fn"}SHD vs. ND56.44% vs. 16.25%23.087\<1.00 × 10^−4^[^\*\*^](#evu220-TF2){ref-type="table-fn"}SPD vs. ND38.74% vs. 16.25%18.991\<1.00 × 10^−4^[^\*\*^](#evu220-TF2){ref-type="table-fn"}[^2][^3]

[@evu220-B73] have claimed that edgetic perturbation is frequently associated with autosomal dominant disease genes. Moreover, it is also known that dominant disease genes are under stronger purifying selections than recessive disease genes because mutation of a single allele of the gene can adequately cause disease in the former set of genes by altering the synthesized gene product ([@evu220-B21]). Hence, to shed lights on the evolutionary conservation of SHD and SPD proteins over ND proteins, we determined the evolutionary rates of edgetically perturbed proteins compared with the rest of the proteins of our data set. As expected, we observed that edgetically perturbed proteins are more evolutionarily constrained than rest of the human proteins (data set using SIFT: d*N*/d*S*~edgetically\ perturbed\ proteins~ = 0.100 \[*n* = 1,546\]; d*N*/d*S*~other\ proteins~ = 0.135 \[*n* = 9,022\]; *P*~MWT~ = 2.89 × 10^−39^; data set using dbNSFP: d*N*/d*S*~edgetically\ perturbed\ proteins~ = 0.090 \[*n* = 2,212\]; d*N*/d*S*~other\ proteins~ = 0.140 \[*n* = 8,356\]; *P*~MWT~ =2.23 × 10^−108^). However, it is also plausible that the underlying difference in evolutionary rates of edgetically perturbed and other proteins is potentially due to variations in sample sizes. To rule out the possibility that our analysis is artifactual, we again considered equal size bins of protein evolutionary rates: bin1 (fast evolving proteins, *n* = 3,523), bin 2 (medium evolving proteins, *n* = 3,523), and bin 3 (slow evolving proteins, *n* = 3,522). In support of our result, we noticed that the proportions of edgetically perturbed proteins and other human proteins are comparatively higher in bin 3 and bin 1, respectively ([fig. 3](#evu220-F3){ref-type="fig"}*A*). Therefore, it is evident that regardless of sample size variations, an inverse correlation exists between edgetic perturbation and protein evolutionary rates. These observations provide a clue that edgetic perturbation may act as a function of protein evolutionary rates of SHD, SPD, and ND genes. F[ig]{.smallcaps}. 3.---Evolutionary rate analyses of interactome network perturbed genes. The bar graphs demonstrate the distributions of (*A*) edgetically perturbed genes and (*B*) side-effect-associated genes in equal size bins classified as (I) fast evolving, (II) medium evolving, and (III) slow evolving groups. MWT was used to find difference between groups. *P* \< 0.05 denotes a significant difference.

Drug-Induced Network Perturbation and Evolutionary Rates of SHD, SPD, and ND genes
----------------------------------------------------------------------------------

Several reports ([@evu220-B36]; [@evu220-B64]) have proposed that pharmacological treatment is necessary to restore the function of the perturbed network as drugs often bind to the interface of the disease-associated proteins. Indeed, we obtained a positive correlation between number of drugs and number of phenotypic defects associated with a protein (considering ND genes: ~Number\ of\ drugs/protein~ ρ^Number\ of\ defects^ = 0.251, *P* = 1.00 × 10^−6^, *n* = 933; excluding ND genes: ~Number\ of\ drugs/protein~ ρ^Number\ of\ defects^= 0.103, *P* = 2.20 × 10^−2^, *n* = 496). In this context, a recent concept is that essentiality and centrality of target proteins may also increase the likelihood of adverse drug side effects, which in turn may help in progression of diseases among individuals ([@evu220-B64]). If it is the case, then we may expect that side-effect-associated drug-targeted proteins would majorly participate in human disease progressions, because all side effects literally do not imply diseases. Accordingly, we observed that proteins with drug side effects are more frequently involved in Mendelian diseases than random expectation (odds ratio = 4.063, *Z* score = 12.440, *P* \< 1.00 × 10^−3^). In general, drugs may cause side effects through network perturbation in single-interface targets by occupying the only shared interaction interface and disintegrating the interactome network ([@evu220-B64]). Interestingly, previous studies have established that singlish (two at most) interface proteins are more likely to disintegrate interactome network by interrupting the links between proteins ([@evu220-B33]; [@evu220-B24]; [@evu220-B70]). Accordingly, we observed that proteins with singlish interaction interfaces (at least two interaction partners for each interface) are highly associated with drug side effects than random expectation (odds ratio = 1.850, *Z* score = 3.837, *P* = 1.00 × 10^−3^). Moreover, the proportions of singlish interface proteins are found to be in the order of SHD (30.30%; 160/528) \> SPD (23.79%; 299/1,257) \> ND proteins (10.72%; 942/8,783) (SHD vs. SPD: *Z* score = 2.875; SHD vs. ND: *Z* score = 13.526; SPD vs. ND: *Z* score = 13.160; *P* \< 5.00 × 10^−3^ in all three cases). Considering the [supplementary data](http://gbe.oxfordjournals.org/lookup/suppl/doi:10.1093/gbe/evu220/-/DC1) set of Kim et al. for singlish interface hub proteins ([@evu220-B33]), we obtained similar result ([table 2](#evu220-T2){ref-type="table"}). Table 2Proportions of Singlish Interface Hubs in Structurally Resolved Network (SIN) for Our Data SetGene PairPercentages*Z* Score*P*SHD vs. SPD8.904.101\<1.00 × 10^−4^[^\*\*^](#evu220-TF3){ref-type="table-fn"}4.05SHD vs. ND8.9022.321\<1.00 × 10^−4^[^\*\*^](#evu220-TF3){ref-type="table-fn"}0.26SPD vs. ND4.0514.714\<1.00 × 10^−4^[^\*\*^](#evu220-TF3){ref-type="table-fn"}0.26[^4]

It is now widely accepted that druggable proteins are highly conserved because substitutions in the interface may obstruct target--drug interactions ([@evu220-B64]). Moreover, singlish interface hubs evolve faster than multi-interface hubs but are generally slow evolving than rest of the proteome due to their hub nature ([@evu220-B33]; [@evu220-B13]). Using drug-targeted proteins, our result also demonstrates that singlish interface proteins are more evolutionarily constrained than the rest (d*N*/d*S*~drug-targeted\ proteins\ with\ singlish\ interface~ = 0.105 (*n* = 216); d*N*/d*S*~drug-targeted\ other\ proteins~ = 0.113 (*n* = 716) and *P*~MWT~ = 2.00 × 10^−3^). Validating the above result, drug side-effect-associated proteins are found to be more conserved than proteins which do not have any known side effects (d*N*/d*S*~proteins\ with\ drug\ side\ effects~ =0.086 \[*n* = 204\]; d*N*/d*S*~proteins\ with\ no\ known\ side\ effect~ = 0.118 \[*n* = 729\] and *P*~MWT~ = 6.17 × 10^−6^). Discrepancy may arise due to differences in sample sizes for drug side effect data in our data set. To avoid such circumstances, we again considered equal sample bins of protein evolutionary rates (bin 1: fast evolving genes; bin 2: medium evolving genes; and bin 3: slow evolving genes). Thus, a higher proportions of side-effect-associated proteins in bin 3 and proteins with no known side effects in bin 1 ([fig. 3](#evu220-F3){ref-type="fig"}*B*) suggest that our analysis is free from sampling bias. These above observations invoke that drug-induced perturbation/drug side effect may act as a determinant of protein evolutionary rates of SHD, SPD, and ND proteins.

Impact of Gene Expression Level, Tissue Expression Breadth, and Functionality on Evolutionary Rates of SHD, SPD, and ND Genes
-----------------------------------------------------------------------------------------------------------------------------

Among all the identified factors, gene expression level is claimed to be the most important correlate of protein evolutionary rates to date ([@evu220-B7]; [@evu220-B16]; [@evu220-B51]). Considering expression level as the mean expression value of a gene in the tissues (using mRNA-seq data of 22 tissue/cell-line samples) where it is found to be expressed ([@evu220-B34]), we also observed a negative correlation between gene expression level and protein evolutionary rates (~Expression\ level~ ρ^d^*^N^*^/d^*^S^* = −0.177, *P* = 1.00 × 10^−6^, *n* = 7,055). Hence, we expected higher expression levels of SHD genes than SPD and ND genes. Estimation of gene expression level revealed the same trend (average gene expression level: SHD = 132.899 \[*n* = 345\]; SPD = 92.085 \[*n* = 897\]; ND = 32.300 \[*n* = 5,813\]). However, SHD genes share no difference in gene expression levels with SPD genes (*P*~MWT~ = 5.31 × 10^−1^). It may be due to the confounding effect of sample size difference. Hence, we grouped all genes equally into three bins according to their expression level (bin 1: lowly expressed \[range: 5.510--10.888, *n* = 2,351\], bin 2: medium expressed \[range: 10.890--21.960, *n* = 2,351\], and bin 3: highly expressed \[range: 21.961--8,041.754, *n* = 2,353\]). Subsequently, we noticed that in all three bins, the differences in proportions of SHD and SPD genes are statistically insignificant (bin 1: SHD vs. SPD = 17.80% vs. 20.04%; bin 2: SHD vs. SPD = 18.56% vs. 21.80%; and bin 3: SHD vs. SPD = 28.98% vs. 29.51%; *P* \> 5.00 × 10^−2^ in all three bins). This observation confirms that gene expression level is insufficient to explain the evolutionary rate variations among genes of our interest.

In their article, [@evu220-B52] have demonstrated that gene expression breadth has a greater influence on protein evolutionary rates than gene expression level because all broadly expressed genes (like genes those are evenly expressed at low levels in all the tissue types) are not necessarily the highly expressed ones (like genes those are expressed at high levels in specific tissue types). Moreover, from an evolutionary perspective, we expected that SHD genes are broadly expressed among all the groups, because broadly expressed genes evolve slower than tissue-specific genes ([@evu220-B71]; [@evu220-B52]). Surprisingly, we noticed a significantly higher tissue-restricted expression of SHD (average expression breadth = 9.316, *n* = 345) genes compared with SPD (average expression breadth = 10.821, *n* = 897) and ND genes (average expression breadth = 11.606, *n* = 5,813) (Kruskal--Wallis test: *P* = 2.99 × 10^−7^), in agreement on a concept that diseases genes tend to be expressed in limited number of tissues ([@evu220-B23]; [@evu220-B37]). However, the lower evolutionary rates of tissue-restricted genes imply that tissue-restricted expression alone is inadequate to explain protein evolutionary rates.

Previously, it has been established that the protein products of genes expressed in only one or few tissues are more often involved in regulatory functions, whereas ubiquitously/broadly expressed genes mainly participate in intracellular core functions ([@evu220-B56]). Using biological processes of gene ontology (GO-BP) ([@evu220-B43]; [@evu220-B3]), we interestingly noticed that number of core functions does not differ between SHD and SPD genes and that between ND and SPD genes, whereas all the group-to-group differences are statistically significant in case of number of regulatory functions ([fig. 4](#evu220-F4){ref-type="fig"}). Subsequently, the higher number of regulatory functions in SHD and SPD genes compared with ND genes ([fig. 4](#evu220-F4){ref-type="fig"}) reconfirmed the statement that disease-associated mutations are more likely to affect regulatory processes ([@evu220-B23]). For a better understanding, we performed functional enrichment analysis (*P* ≤ 10^−3^) of our gene set using GOrilla (Gene Ontology enRIchment anaLysis and visuaLizAtion tool \[[@evu220-B17]\]). By this means, the only regulatory process found to be enriched in all the three groups (out of false discovery rate corrected 40 SHD, 88 SPD, and 304 ND significant GO terms) of our data set was transmembrane transport (GO: 0055085, *P* values for GO: 0055085 in SHD, SPD, and ND genes are 1.86 × 10^−8^, 6.67 × 10^−4^, and 1.19 × 10^−9^, respectively). At this point, it should be mentioned that genes involved in transmembrane transport are often tissue restricted, disease-causing deleterious mutation prone, and evolve slowly at protein level due to their higher buried residue content ([@evu220-B48]; [@evu220-B56]; [@evu220-B47]). Therefore, considering transmembrane proteins (proteins containing transmembrane helices), our analyses also confirmed the same (~Transmembrane\ helices/protein~ ρ^Expression\ breadth^= −0.168, *P* = 1.00 × 10^−6^, *n* = 1,490; ~Transmembrane\ helices/protein~ ρ^Deleterious\ SNPs/gene^= 0.175, *P* = 1.00 × 10^−6^, *n* = 1,165; ~Transmembrane\ helices/protein~ ρ^d^*^N^*^/d^*^S^* = −0.066, *P* = 1.00 × 10^−3^, *n* = 2,577). Moreover, in support of our studies, the proportions of transmembrane proteins are found to be in the order of SHD (38.26%; 202/528) \> SPD (29.83%; 375/1,257) \> ND (22.77%; 2,000/8,783) (*P* \< 1.00 × 10^−4^ in all three cases). F[ig]{.smallcaps}. 4.---Assessment of core and regulatory processes of our gene sets. In the left cluster, the bar graph exhibits that SPD genes share no difference (*P* \> 0.05) in number of core functions to SHD or ND genes. All the three groups of genes show considerable differences in their number of regulatory functions (right cluster). Error bars represent the standard error of the mean in all three groups of genes.

To understand the relationship between transmembrane transport and tissue expression breadth on protein evolutionary rate, we split all the genes into three equally spaced bins according to their tissue expression breadth (bin 1: lower breadth \[range: 1--7, *n* = 2,828\], bin 2: medium breadth \[range: 8--14, *n* = 1,444\], and bin 3: higher breadth \[range: 15--22, *n* = 2,783\]). Consequently, for tissue-restricted genes (bin 2), the correlation between expression breadth and evolutionary rates disappears (~Tissue\ expression\ breadth~ ρ^d^*^N^*^/d^*^S^* = 0.041, *P* = 1.23 × 10^−1^, *n* = 1,444), whereas the correlation between number of transmembrane helices and protein evolutionary rates appears better than previous (~Transmembrane\ helices/protein~ ρ^d^*^N^*^/d^*^S^* = −0.189, *P* = 1.00 × 10^−3^, *n* = 334) ([fig. 5](#evu220-F5){ref-type="fig"}). Moreover, the existence of a significant correlation between tissue expression breadth and the number of transmembrane helices (~Transmembrane\ helices/protein~ ρ^Expression\ breadth^= −0.122, *P* = 2.60 × 10^−2^, *n* = 334) suggests that tissue expression breadth and transmembrane transport may simultaneously affect protein evolutionary rates ([fig. 5](#evu220-F5){ref-type="fig"}). Using equally populated bins (according to tissue expression breadth), a similar result was obtained (data not shown). Further considering genes having both (number of transmembrane helices and tissue expression breadth) data available, we noticed considerably (*P*~MWT~ = 1.10 × 10^−6^) lower evolutionary rates for such genes (average d*N*/d*S* = 0.113, *n* = 1,490) compared with all human genes in our data set (average d*N*/d*S* = 0.130, *n* = 10,568). Therefore, it is evident from our analysis that the interaction term of tissue expression breadth and transmembrane transport may influence the evolutionary rates of SHD, SPD, and ND genes. F[ig]{.smallcaps}. 5.---Relationships among transmembrane transport, tissue expression breadth, and protein evolutionary rates. In each cluster, tmhmm, EB, and d*N*/d*S* represent transmembrane helix count per protein, tissue expression breadth, and protein evolutionary rate, respectively. For each bin, range of tissue expression breadth has been mentioned in the parentheses. Significance: \**P* value \< 0.05, \*\**P* value \< 0.01, and \*\*\**P* value \< 0.001.

Relative Contribution of Parameters on Protein Evolutionary Rates
-----------------------------------------------------------------

In this study, we identified the importance of two distinct network perturbation models and the interaction term of tissue expression breadth and transmembrane transport (three out of the six predictors) on protein evolutionary rates except number of phenotypic defects and gene expression levels. Because edgetic perturbation and drug-induced perturbation may certainly have different molecular consequences on human disease progressions and on protein evolutionary rates, it is necessary to understand the relative contributions of all the factors in dictating the variation of protein evolutionary rates. In this regard, ANCOVA helps to understand the functional relationships between the measurement variables, while at least one of the predictor variables is categorical in nature ([@evu220-B12]). However, a number of known evolutionary rate determinants (such as gene recombination rate, paralog number, protein length, and complex association number) were shown to be associated with human genetic diseases ([@evu220-B44]; [@evu220-B7]; [@evu220-B37]; [@evu220-B8]; [@evu220-B72]). Such biological parameters are likely to be confounding factors in our analysis. We, therefore, included the aforementioned four genomic covariates in our ANCOVA model. Thus, by using the backward elimination approach, our ANCOVA model (*F* = 10.101, *P* \< 1.00 × 10^−4^, *R*^2^= 13.4%) demonstrated that drug-induced (side effect/no side effect) perturbation model (β = −0.278, *P* = 2.98 × 10^−4^), gene paralog number (β = −0.154, *P* = 4.20 × 10^−2^), and the interaction term of expression breadth-transmembrane transport (β = −0.140, *P* = 4.90 × 10^−2^) independently affects protein evolutionary rates.

However, the result of an ordinary regression analysis can be misleading as it does not take into account predictor collinearity ([@evu220-B16]). To rule out such possibility, principal component regression method can be applied ([@evu220-B16]). Each independent principal component is linear combinations of the original predictor variables ([@evu220-B16]). We, therefore, carried out categorical principal component analysis due to the presence of categorical predictors in our data set. Subsequent regression of the response variable (protein evolutionary rate) on the principal component scores revealed that two components (PC1 and PC2) made significant contributions to the regression model (*F* = 16.138, *P* = 3.70 × 10^−7^, *R*^2^= 14.6%). Among them, 11.2% variance of protein evolutionary rates is explained by PC1 (β = −0.343, *P* = 1.87 × 10^−6^) and PC2 (β = −0.196, *P* = 5.00 × 10^3^) explains 3.4% evolutionary rate variance. PC1 primarily measures paralog numbers, protein length, and drug-induced perturbation, whereas PC2 measures the interaction term of expression breadth-transmembrane transport and protein complex association number ([table 3](#evu220-T3){ref-type="table"}). Thus, from both of our ANCOVA and principal component regression analyses, we infer that except edgetic perturbation (perturbed/nonperturbed) model, drug-induced (side effect/no side effect) perturbation model, and the interaction term of expression breadth-transmembrane transport have independent effects on protein evolutionary rates. It is probably due to the fact that total network disruption (all edge removals in the interactome network) by drug-induced perturbation is a combination of several edgetic perturbations. Hence, drug-induced perturbation has reasonably severe effect on gene phenotypes than edgetic perturbation. Table 3Result of Categorical Principal Component Analysis on Seven Predictor Variables of Our Data SetPredictorsPercent ContributionsPC1PC2Gene paralog number**23.78**7.17Gene recombination rate19.8614.03EB\*tmhmm7.06**36.81**Protein length**24.53**8.29Complex association number4.35**32.59**Drug induced perturbation**20.42**1.11Edgetic perturbation0.000.00[^5]

Discussion
==========

In the field of molecular evolution, there are commonalities behind disease mutations which have been detected, but there are more complexities to disease mutations, which are yet to be discerned. In this work, we analyzed the evolutionary rates of human autosomal phenotypic disease (SHD and SPD) genes originated by mutation(s) in a single gene (monogenic) in comparison to ND genes. For evolutionary rate study, we considered widely used human--mouse orthologous pair ([@evu220-B40], [@evu220-B41]; [@evu220-B8]; [@evu220-B22]). The most common reason is the functional conservation between human and mouse in normal and pathological conditions ([@evu220-B22]). However, it has been emphasized that the murid rodents have higher divergence time (∼95 Ma) than primates ([@evu220-B14]). Hence, an alternative way is to consider human--chimpanzee or human--macaque ortholog to compute protein evolutionary rate. Again, for closely related taxa, it has been criticized that estimation of evolutionary rate can be misleading as d*S* might suffer from the uncertainty due to potentially smaller branch lengths ([@evu220-B68]). We, therefore, continued our evolutionary rate analysis using human--mouse orthologous pair. Consistent to the previous studies ([@evu220-B6]; [@evu220-B8]) that disease genes are conserved than ND genes, we established that genes with more defects are strongly constrained compared with the genes with single/no defect. However, we noticed that number of defects is unable to explain the evolutionary rate differences of SHD, SPD, and ND genes. Hence, to clarify the underlying reasons of evolutionary rate variations among SHD, SPD, and ND genes, we incorporated functional (core/regulatory), gene expression related (mRNA expression level and tissue expression breadth), and structural (network perturbation due to edge removal and network perturbation due to drug binding of singlish interaction interface) features of protein evolutionary rates in this communication.

Malfunctioning/disruption of a biological function often lead to the progression of human diseases ([@evu220-B43]; [@evu220-B30]). Distinct disease genes can be traced through interactome networks ([@evu220-B23]). To this end, edge removal/edgetic perturbation model offers an explanatory power that why different mutations from the same gene produce different phenotypes ([@evu220-B73]). We as expected obtained higher disease association for edgetically perturbed proteins. Prior studies have already established that human disease genes evolve slower than ND genes ([@evu220-B6]; [@evu220-B8]). Hence, frequent disease involvements practically support the lower evolutionary rates of edgetically perturbed proteins compared with other proteins those are not found to be edgetically perturbed. In this context, it should be mentioned that drugs used for treating a disease may in turn cause diseases through increased side effects. Such side effects are promoted by drugs especially in single/singlish interface targets by occupying its interaction interface(s) ([@evu220-B24]; [@evu220-B70]; [@evu220-B64]). In our study, for the first time, we have noticed that proteins with singlish interaction interfaces are highly associated with drug side effects and such side-effect-associated proteins are evolutionarily more conserved than rest of the proteins. However, it has been recently found that side-effect-associated proteins are essential in nature and occupy central position in the interactome networks ([@evu220-B64]). Because, centrality and essentiality are negative correlates of protein evolutionary rates ([@evu220-B25]), our findings are reasonable in this ground. Further comparison of both the two network perturbation models revealed a higher dominance of drug-induced perturbation over the edgetic perturbation model. We reasoned that drug-induced perturbation can totally disrupt a network and, thus, is a combination of several edgetic perturbations.

One basic feature that is widely related to protein evolution is expression level of a gene, which shares a negative correlation to protein evolutionary rates ([@evu220-B7]; [@evu220-B16]). Interestingly, we did not notice any difference in gene expression levels between ND and SHD genes. It may be due to the fact that broadly expressed genes, which are evenly expressed at low levels in all tissues are not necessarily the highly expressed ones that are expressed at high levels in specific tissues ([@evu220-B52]). However, in contrast to the common view ([@evu220-B67]), our tissue expression study revealed a higher tissue-restricted expression of highly conserved disease genes. Although, we obtained a significant difference in tissue expression breadth within SHD, SPD, and ND genes, the above unexpected observation confirms that tissue expression breadth alone cannot explain the variation in evolutionary rates among genes of our interest. To find a reason, we concentrated on protein functions as tissue-specific components often need to perform certain regulatory functions ([@evu220-B56]). Further elaborative study revealed that only regulatory functions can effectively clarify the evolutionary rate differences among genes of our interest, whereas core functions are found to be inadequate. One possible scenario could be that core functions are required for basic processes within the cell and always need to be switched on. Therefore, the number of such functions required by any cell should be relatively similar ([@evu220-B53]). Because disease-related mutations compatible with survival are more likely to be maintained a population, cells prefer to endure deleterious mutations in regulatory pathways ([@evu220-B23]). Interestingly, a comprehensive analysis on regulatory functions identified "transmembrane transport" as a common function present on all three groups. Proteins involve in such function is often tissue-restricted and evolve slower at the protein level ([@evu220-B48]; [@evu220-B47]). Hence, presence of higher proportion of transmembrane protein in human disease category makes it evident that tissue expression breadth and transmembrane transport simultaneously influence the evolutionary rates of SHD, SPD, and ND genes.

To summarize, our analysis established a link between human phenotypic disease network and protein evolution, which will definitely help in understanding human monogenic disease etiology and the underlying mechanism of disease progressions from a single gene. The localization of disease genes in regulatory pathways is especially important for identifying new disease candidates. Till date, majority of the target-based drug identification depends on observable phenotypic defects. However, for the first time, our communication has provided useful information on the relative risk associated with drug perturbed network over edge perturbed network. Our work emphasized that further thorough investigations are needed to improve drug efficacy (i.e., drug with minimal side effects), especially for SHD and SPD genes. With this work, we can make a substantial progress in future medicine.

Supplementary Material
======================

[Supplementary table S1](http://gbe.oxfordjournals.org/lookup/suppl/doi:10.1093/gbe/evu220/-/DC1) is available at *Genome Biology and Evolution* online (<http://www.gbe.oxfordjournals.org/>).
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